We are live on ! Find out more
ADIM

Alpha DNA Investment Management Portfolio holdings

AUM $8.98M
1-Year Est. Return 26.05%
This Fund
S&P 500
This Quarter Est. Return
+12.81%
1 Year Est. Return
+26.05%
3 Year Est. Return
+134.39%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$283M
AUM Growth
+$162M
Cap. Flow
+$72.6M
Cap. Flow %
25.66%
Top 10 Hldgs %
42.53%
Holding
215
New
70
Increased
65
Reduced
14
Closed
66

Top Buys

Rank Stock Value
1
MCD icon
McDonald's
MCD
+$2.38M
2
WMT icon
Walmart Inc
WMT
+$2.38M
3
JPM icon
JPMorgan Chase
JPM
+$2.13M
4
FATE icon
Fate Therapeutics
FATE
+$1.92M
5
FTNT icon
Fortinet
FTNT
+$1.5M

Top Sells

Rank Stock Value
1
XOM icon
ExxonMobil
XOM
+$2.05M
2
PFE icon
Pfizer
PFE
+$1.44M
3
CVS icon
CVS Health
CVS
+$1.41M
4
MET icon
MetLife
MET
+$1.4M
5
DE icon
Deere & Co
DE
+$1.24M

Sector Composition

Rank Sector Weight
1 Financials 18.71%
2 Technology 15.05%
3 Industrials 8.12%
4 Healthcare 7.38%
5 Energy 5.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SM icon
201
SM Energy
SM
$7.73B
– –
-17,845
Closed -$671K
STNG icon
202
Scorpio Tankers
STNG
$3.72B
– –
-14,608
Closed -$614K
TEL icon
203
TE Connectivity
TEL
$63.3B
– –
-6,137
Closed -$677K
TNK icon
204
Teekay Tankers
TNK
$2.69B
– –
-19,385
Closed -$533K
TT icon
205
Trane Technologies
TT
$106B
– –
-6,849
Closed -$991K
TTMI icon
206
TTM Technologies
TTMI
$13.8B
– –
-35,985
Closed -$474K
WCC
207
WESCO International
WCC
$17.8B
– –
-4,333
Closed -$517K
WSM icon
208
Williams-Sonoma
WSM
$29.5B
– –
-11,322
Closed -$667K
ZION icon
209
Zions Bancorporation
ZION
$10.4B
– –
-10,445
Closed -$531K
BECN
210
DELISTED
Beacon Roofing Supply, Inc.
BECN
– –
-9,922
Closed -$542K
GTHX
211
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-42,477
Closed -$530K
LTHM
212
DELISTED
Livent Corporation
LTHM
– –
-18,082
Closed -$554K
NEX
213
DELISTED
NexTier Oilfield Solutions Inc.
NEX
– –
-75,280
Closed -$557K
CLR
214
DELISTED
CONTINENTAL RESOURCES INC.
CLR
– –
-12,529
Closed -$837K
ESTE
215
DELISTED
Earthstone Energy Inc. Class A Common Stock
ESTE
– –
-48,725
Closed -$600K
5 6 7 8
9

Similar funds

CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
AI
Allostery Investments Stamford, Connecticut $7.85M AUM
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return

Alpha DNA Investment Management's Q4 2022 Portfolio in Review

As of Q4 2022, Alpha DNA Investment Management held 215 positions worth $283M, up 135% from $120M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Alpha DNA Investment Management deployed $72.6M of net new capital in Q4 2022, opening 70 new positions and adding to 65 existing holdings. Its largest new stake was Fate Therapeutics: 102,094 shares worth $1.03M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 19% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was ExxonMobil, an estimated $2.05M trimmed.

  • Alpha DNA Investment Management's largest Q4 2022 buy was Fate Therapeutics: 102,094 shares worth $1.03M.
  • Alpha DNA Investment Management added most to McDonald's in Q4 2022, an estimated $2.38M increase.
  • Alpha DNA Investment Management's biggest Q4 2022 reduction was ExxonMobil, cutting an estimated $2.05M.
  • Alpha DNA Investment Management fully exited CVS Health in Q4 2022, selling an estimated $1.41M.
  • Alpha DNA Investment Management's ten largest holdings make up 43% of its $283M portfolio in Q4 2022.
  • Alpha DNA Investment Management opened 70 new positions and closed 66 in Q4 2022.
  • Alpha DNA Investment Management's portfolio value rose 135% quarter-over-quarter to $283M.

Based on Alpha DNA Investment Management's 13F filing for Q4 2022, filed 27 Jan 2023.